Annexon, Inc. (NASDAQ:ANNX) EVP Sells $16,379.55 in Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Dean Richard Artis sold 5,515 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $2.97, for a total transaction of $16,379.55. Following the completion of the sale, the executive vice president now directly owns 83,814 shares in the company, valued at approximately $248,927.58. This trade represents a 6.17 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Annexon Trading Down 0.7 %

Annexon stock opened at $2.81 on Friday. The company’s 50-day moving average price is $4.26 and its two-hundred day moving average price is $5.55. The stock has a market cap of $299.52 million, a price-to-earnings ratio of -2.68 and a beta of 1.07. Annexon, Inc. has a 52 week low of $2.63 and a 52 week high of $8.40.

Analysts Set New Price Targets

A number of analysts recently weighed in on ANNX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Annexon in a research note on Tuesday, December 17th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $15.80.

Hedge Funds Weigh In On Annexon

Several hedge funds have recently made changes to their positions in ANNX. SG Americas Securities LLC grew its stake in shares of Annexon by 117.8% in the 3rd quarter. SG Americas Securities LLC now owns 32,763 shares of the company’s stock worth $194,000 after purchasing an additional 17,723 shares during the last quarter. Creative Planning grew its stake in shares of Annexon by 29.5% in the 3rd quarter. Creative Planning now owns 34,779 shares of the company’s stock worth $206,000 after purchasing an additional 7,914 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Annexon by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 259,404 shares of the company’s stock worth $1,536,000 after purchasing an additional 66,792 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after purchasing an additional 3,355 shares during the last quarter. Finally, Mutual of America Capital Management LLC grew its stake in shares of Annexon by 3.1% in the 3rd quarter. Mutual of America Capital Management LLC now owns 659,254 shares of the company’s stock worth $3,903,000 after purchasing an additional 19,681 shares during the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.